Chinese pharma powerhouse Hansoh joins fledgling biotechs in the Hong Kong IPO line
More than four months after first opening its doors to a big crowd of R&D focused biotechs, the Hong Kong Stock Exchange has seen a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.